Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024

世界の遺伝子治療市場:ベクター別[非ウイルス(オリゴヌクレオチド)、ウイルス(レトロウイルス(ガンマレトロウイルス、レンチウイルス))、アデノ随伴]、疾患別(がん、神経疾患)、デリバリー方法別(In Vivo、Ex Vivo)、地域別

◆タイトル:Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024
◆商品コード:BT 7506
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年1月30日
◆ページ数:136
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は、遺伝子治療の世界市場規模が2019年38億ドルから2024年130億ドルまで年平均27.8%成長すると予測しています。本調査レポートでは、世界の遺伝子治療市場を広く調査・分析し、市場概要、ベクター別(非ウイルスベクター、ウイルスベクター)分析、疾患別(神経疾患、がん、肝疾患、デュシェンヌ型筋ジストロフィー、その他)分析、デリバリー方法別(In Vivo遺伝子治療、Ex Vivo遺伝子治療)分析、地域別分析、競合動向、企業概要などで取りまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の遺伝子治療市場:ベクター別(非ウイルスベクター、ウイルスベクター)
・世界の遺伝子治療市場:疾患別(神経疾患、がん、肝疾患、デュシェンヌ型筋ジストロフィー、その他)
・世界の遺伝子治療市場:デリバリー方法別(In Vivo遺伝子治療、Ex Vivo遺伝子治療)
・世界の遺伝子治療市場:地域別
・競合動向
・企業概要

“High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market”
The global gene therapy market is projected to reach USD 13.0 billion by 2024 from USD 3.8 billion in 2019, at a CAGR of 27.8% during the forecast period. The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. In addition, the strong product pipeline of market players is expected to offer significant growth opportunities in the coming years. However, the high cost of treatment is expected to hamper market growth to a certain extent in the coming years.

“Neurological diseases segment accounted for the largest share of the gene therapy market, by indication, in 2018”
Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. This can be attributed to the increasing number of gene therapy products being approved for the treatment of neurological diseases and the high market penetration of oligonucleotide-based gene therapies.

“Viral vectors segment to register the highest growth in the gene therapy market during the forecast period”
The gene therapy market, by vector, has been segmented into viral and non-viral vectors. In 2018, the non-viral vectors segment accounted for the largest share of this market. However, the viral vectors segment is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing demand for CAR T-based gene therapies and the rising incidence of cancer.

“North America will continue to dominate the gene therapy market during the forecast period”
Geographically, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the gene therapy market, followed by Europe. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 32%, Tier 2 – 44%, and Tier 3 – 24%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 50%, Europe – 32%, Asia Pacific – 10%, and Rest of the World – 8%

List of companies profiled in the report
• Amgen, Inc. (US)
• Biogen (US)
• Novartis AG (Switzerland)
• Gilead Sciences, Inc. (US)
• Spark Therapeutics, Inc. (US)
• MolMed S.p.A. (Italy)
• Orchard Therapeutics plc. (UK)
• SiBiono GeneTech Co., Ltd. (China)
• Alnylam Pharmaceuticals, Inc. (US)
• Human Stem Cells Institute (Russia)
• AnGes, Inc. (Japan)
• Dynavax Technologies (US)
• Jazz Pharmaceuticals, Inc. (Ireland)
• Akcea Therapeutics (US)
• bluebird bio, Inc. (US)
• uniQure NV (Netherlands)
• AGTC (US)
• Mustang Bio (US)
• Cellectis (France)
• Poseida Therapeutics, Inc. (US)
• Sangamo Therapeutics (US)

Research Coverage:
This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments (by vector, indication, delivery method, and region). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. Also, this report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

【レポートの目次】

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitation
1.6 Stakeholders
2 Research Methodology (Page No. – 19)
2.1 Research Data
2.2 Secondary Data
2.2.1 Secondary Source
2.3 Primary Data
2.4 Market Size Estimation
2.4.1 Bottom-Up Approach
2.4.2 Bottom-Up Approach for Non-Viral Vectors and Viral Vectors Market
2.4.3 Growth Forecast
2.5 Market Breakdown and Data Triangulation
2.6 Assumptions for the Study
3 Executive Summary (Page No. – 25)
4 Premium Insights (Page No. – 28)
4.1 Gene Therapy Market Overview
4.2 North America: Market, By Vector (2018)
4.3 Geographical Snapshot of the Market
5 Market Overview (Page No. – 30)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Incidence of Cancer and Other Target Diseases
5.2.1.2 Product Approvals
5.2.1.3 Funding for Gene Therapy Research
5.2.2 Opportunities
5.2.2.1 Strong Product Pipeline
5.2.3 Challenges
5.2.3.1 High Cost of Treatments
6 Gene Therapy Market, By Vector (Page No. – 35)
6.1 Introduction
6.2 Non-Viral Vectors
6.2.1 Oligonucleotides
6.2.1.1 North America Accounted for the Largest Share of the Oligonucleotides Segment
6.2.2 Other Non-Viral Vectors
6.3 Viral Vectors
6.3.1 Retroviral Vectors
6.3.1.1 Gamma-Retroviral Vectors
6.3.1.1.1 The Availability of A Wide Range of Gamma-Retroviral Vectors Supports the Growth of This Market
6.3.1.2 Lentiviral Vectors
6.3.1.2.1 North America Accounted for the Largest Share of the Lentiviral Vectors Segment
6.3.2 Adeno-Associated Virus Vectors
6.3.2.1 Possible Applications in In Vivo Applications Have Driven Interest in Adeno-Associated Virus Vectors
6.3.3 Other Viral Vectors
7 Gene Therapy Market, By Indication (Page No. – 44)
7.1 Introduction
7.2 Neurological Diseases
7.2.1 Neurological Diseases Account for the Largest Share of the Market
7.3 Cancer
7.3.1 Cancer is Expected to Show the Highest Growth in This Market
7.4 Hepatological Diseases
7.4.1 Increasing Prevalence of Hepatitis B Infections Will Support Market Growth
7.5 Duchenne Muscular Dystrophy
7.5.1 North America Accounted for the Largest Share of the Dmd Gene Therapy Segment
7.6 Other Indications
8 Gene Therapy Market, By Delivery Method (Page No. – 50)
8.1 Introduction
8.2 In Vivo Gene Therapy
8.3 Ex Vivo Gene Therapy
9 Gene Therapy Market, By Region (Page No. – 53)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 The US Dominates the Global Market
9.2.2 Canada
9.2.2.1 Growing Burden of Cancer Will Support Market Growth in Canada
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany Accounted for the Largest Share of the Market in Europe
9.3.2 France
9.3.2.1 Increasing Cancer Incidence Supports Market Growth
9.3.3 UK
9.3.3.1 Rising Incidence of Melanoma Will Drive Demand in the UK
9.3.4 Italy
9.3.4.1 High Incidence of Targeted Diseases and Increasing Per Capita Healthcare Spending Will Drive Market Growth in Italy
9.3.5 Spain
9.3.5.1 Non-Viral Vectors Dominate the Spanish Market, By Vector
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Japan Dominates the APAC Market for Gene Therapy
9.4.2 China
9.4.2.1 Rising Prevalence of Cancer and Established Base for Gene Therapy are Supportive Factors in China
9.4.3 Rest of APAC
9.5 Rest of the World
10 Competitive Landscape (Page No. – 89)
10.1 Overview
10.2 Market Share Analysis, 2018
10.3 Key Strategies
10.4 Competitive Leadership Mapping (2018)
10.4.1 Visionary Leaders
10.4.2 Innovators
10.4.3 Dynamic Differentiators
10.4.4 Emerging Companies
11 Company Profiles (Page No. – 95)
(Business Overview, Products Offered, Recent Developments & MnM View)*
11.1 Biogen
11.2 Gilead Sciences, Inc.
11.3 Amgen, Inc.
11.4 Novartis AG
11.5 Orchard Therapeutics Plc
11.6 Spark Therapeutics, Inc. (A Part of ýHoffmann-La Roche)
11.7 Molmed S.P.A.
11.8 Anges, Inc.
11.9 Bluebird Bio, Inc.
11.10 Human Stem Cells Institute (HSCI)
11.11 SIBIONO Genetech Co., Ltd.
11.12 Shanghai Sunway Biotech Co., Ltd
11.13 Uniqure N.V.
11.14 Gensight Biologics S.A.
11.15 Celgene Corporation (A Bristol-Myers Squibb Company)
11.16 Cellectis
11.17 Sangamo Therapeutics
11.18 Mustang Bio
11.19 AGTC (Applied Genetic Technologies Corporation)
11.20 Poseida Therapeutics, Inc.
*Details on Business Overview, Products Offered, Recent Developments & MnM View Might Not Be Captured in Case of Unlisted Companies.
12 Appendix (Page No. – 123)
12.1 Insights From Industry Experts
12.2 Discussion Guide
12.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.4 Available Customization
12.5 Related Reports
12.6 Author Details

List of Tables (127 Tables)
Table 1 Global Cancer Incidence, 2018 vs. 2025
Table 2 Product Approvals, 2015–2019
Table 3 Gene Therapy Market: List of Some Pipeline Drugs
Table 4 Price of Gene Therapy Products, 2018
Table 5 Market, By Vector, 2017–2024 (USD Million)
Table 6 Market for Non-Viral Vectors, By Region, 2017–2024 (USD Million)
Table 7 Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 8 Market for Oligonucleotides, By Region, 2017–2024 (USD Million)
Table 9 Market for Other Non-Viral Vectors, By Region, 2017–2024 (USD Million)
Table 10 Market for Viral Vectors, By Region, 2017–2024 (USD Million)
Table 11 Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 12 Market for Retroviral Vectors, By Region, 2017–2024 (USD Million)
Table 13 Market for Retroviral Vectors, By Type, 2017–2024 (USD Million)
Table 14 Market for Gamma-Retroviral Vectors, By Region, 2017–2024 (USD Million)
Table 15 Market for Lentiviral Vectors, By Region, 2017–2024 (USD Million)
Table 16 Market for Aav Vectors, By Region, 2017–2024 (USD Million)
Table 17 Market for Other Viral Vectors, By Region, 2017–2024 (USD Million)
Table 18 Market, By Indication, 2017–2024 (USD Million)
Table 19 Market for Neurological Diseases, By Region, 2017–2024 (USD Million)
Table 20 Number of Cancer Patients, By Type, 2012–2030
Table 21 Market for Cancer, By Region, 2017–2024 (USD Million)
Table 22 Market for Hepatological Diseases, By Region, 2017–2024 (USD Million)
Table 23 Gene Therapy Market for Dmd, By Region, 2017–2024 (USD Million)
Table 24 Market for Other Indications, By Region, 2017–2024 (USD Million)
Table 25 Market, By Delivery Method, 2017–2024 (USD Million)
Table 26 In Vivo Gene Therapy Market, By Region, 2017–2024 (USD Million)
Table 27 Ex Vivo Gene Therapy Market, By Region, 2017–2024 (USD Million)
Table 28 Market, By Region, 2017–2024 (USD Million)
Table 29 North America: Market, By Country, 2017–2024 (USD Million)
Table 30 North America: Market, By Vector, 2017–2024 (USD Million)
Table 31 North America: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 32 North America: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 33 North America: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 34 North America: Gene Therapy Market, By Delivery Method, 2017–2024 (USD Million)
Table 35 North America: Market, By Indication,2017–2024 (USD Million)
Table 36 List of Gene Therapy Pipeline Candidates in the Us-Based Companies
Table 37 US Fda Gene Therapy Product Approvals
Table 38 US: Gene Therapy Market, By Vector, 2017–2024 (USD Million)
Table 39 US: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 40 US: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 41 US: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 42 US: Market, By Delivery Method, 2017–2024 (USD Million)
Table 43 US: Market, By Indication, 2017–2024 (USD Million)
Table 44 Canada: Market, By Vector, 2017–2024 (USD Million)
Table 45 Canada: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 46 Canada: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 47 Canada: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 48 Canada: Market, By Delivery Method, 2017–2024 (USD Million)
Table 49 Canada: Market, By Indication, 2017–2024 (USD Million)
Table 50 Europe: Gene Therapy Market, By Country, 2017–2024 (USD Million)
Table 51 Europe: Market, By Vector, 2017–2024 (USD Million)
Table 52 Europe: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 53 Europe: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 54 Europe: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 55 Europe: Market, By Delivery Method, 2017–2024 (USD Million)
Table 56 Europe: Market, By Indication, 2017–2024 (USD Million)
Table 57 Incidence of Hematology Cancers, By Type, 2018 vs. 2025
Table 58 Germany: Market, By Vector, 2017–2024 (USD Million)
Table 59 Germany: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 60 Germany: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 61 Germany: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 62 Germany: Gene Therapy Market, By Delivery Method, 2017–2024 (USD Million)
Table 63 Germany: Market, By Indication, 2017–2024 (USD Million)
Table 64 France: Market, By Vector, 2017–2024 (USD Million)
Table 65 France: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 66 France: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 67 France: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 68 France: Gene Therapy Market, By Delivery Method, 2017–2024 (USD Million)
Table 69 France: Market, By Indication, 2017–2024 (USD Million)
Table 70 Incidence of Cancers, By Type, 2018 vs. 2025
Table 71 UK: Market, By Vector, 2017–2024 (USD Million)
Table 72 UK: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 73 UK: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 74 UK: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 75 UK: Market, By Delivery Method, 2017–2024 (USD Million)
Table 76 UK: Market, By Indication, 2017–2024 (USD Million)
Table 77 Italy: Market, By Vector, 2017–2024 (USD Million)
Table 78 Italy: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 79 Italy: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 80 Italy: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 81 Italy: Market, By Delivery Method, 2017–2024 (USD Million)
Table 82 Italy: Gene Therapy Market, By Indication, 2017–2024 (USD Million)
Table 83 Spain: Market, By Vector, 2017–2024 (USD Million)
Table 84 Spain: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 85 Spain: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 86 Spain: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 87 Spain: Market, By Delivery Method, 2017–2024 (USD Million)
Table 88 Spain: Market, By Indication, 2017–2024 (USD Million)
Table 89 RoE: Market, By Vector, 2017–2024 (USD Million)
Table 90 RoE: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 91 RoE: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 92 RoE: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 93 RoE: Gene Therapy Market, By Delivery Method, 2017–2024 (USD Million)
Table 94 RoE: Market, By Indication, 2017–2024 (USD Million)
Table 95 Asia Pacific: Market, By Country, 2017–2024 (USD Million)
Table 96 Asia Pacific: Market, By Vector, 2017–2024 (USD Million)
Table 97 Asia Pacific: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 98 Asia Pacific: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 99 Asia Pacific: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 100 Asia Pacific: Gene Therapy Market, By Delivery Method, 2017–2024 (USD Million)
Table 101 Asia Pacific: Market, By Indication, 2017–2024 (USD Million)
Table 102 Japan: Market, By Vector, 2017–2024 (USD Million)
Table 103 Japan: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 104 Japan: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 105 Japan: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 106 Japan: Market, By Delivery Method, 2017–2024 (USD Million)
Table 107 Japan: Market, By Indication, 2017–2024 (USD Million)
Table 108 China: Market, By Vector, 2017–2024 (USD Million)
Table 109 China: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 110 China: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 111 China: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 112 China: Gene Therapy Market, By Delivery Method, 2017–2024 (USD Million)
Table 113 China: Market, By Indication, 2017–2024 (USD Million)
Table 114 Rest of APAC: Market, By Vector, 2017–2024 (USD Million)
Table 115 Rest of APAC: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 116 Rest of APAC: Market for Viral Vectors, By Type, 2017–2024 (USD Million)
Table 117 Rest of APAC: Retroviral Vectors Market, By Type, 2017–2024 (USD Million)
Table 118 Rest of APAC: Market, By Delivery Method, 2017–2024 (USD Million)
Table 119 Rest of APAC: Market, By Indication, 2017–2024 (USD Million)
Table 120 RoW: Market, By Vector, 2017–2024 (USD Million)
Table 121 RoW: Market for Non-Viral Vectors, By Type, 2017–2024 (USD Million)
Table 122 RoW: Market, By Delivery Method, 2017–2024 (USD Million)
Table 123 RoW: Market, By Indication, 2017–2024 (USD Million)
Table 124 Product Approvals, 2016–2019
Table 125 Acquisitions, 2016–2019
Table 126 Collaborations, Agreements and Partnerships, 2016–2019
Table 127 Expansions, 2016–2019

List of Figures (25 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Data Triangulation Methodology
Figure 4 Gene Therapy Market, By Vector, 2019 vs. 2024 (USD Million)
Figure 5 Market, By Delivery Method, 2019 vs. 2024 (USD Million)
Figure 6 Market, By Indication, 2019 vs. 2024 (USD Million)
Figure 7 Market, By Region, 2019 vs. 2024
Figure 8 High Incidence of Cancer & Other Targeted Diseases to Drive Market Growth
Figure 9 Non-Viral Vectors Accounted for the Largest Share of the North American Market in 2018
Figure 10 Countries in North America to Register the Highest Growth Rate During the Forecast Period
Figure 11 Gene Therapy Market: Drivers, Opportunities, and Challenges
Figure 12 Non-Viral Segment Will Continue to Dominate the Market During the Forecast Period
Figure 13 Neurology Will Continue to Dominate the Market During the Forecast Period
Figure 14 In Vivo Segment Will Continue to Dominate the Market During the Forecast Period
Figure 15 North America Region Will Continue to Dominate the Market During the Forecast Period
Figure 16 North America: Gene Therapy Market Snapshot
Figure 17 Key Developments in the Market
Figure 18 Market, Market Share Analysis, 2018
Figure 19 MnM Dive-Vendor Comparison Matrix: Market
Figure 20 Biogen: Company Snapshot
Figure 21 Gilead Sciences, Inc.: Company Snapshot
Figure 22 Amgen, Inc.: Company Snapshot
Figure 23 Novartis AG: Company Snapshot
Figure 24 Spark Therapeutics, Inc.: Company Snapshot
Figure 25 Anges, Inc.: Company Snapshot

★調査レポート[世界の遺伝子治療市場:ベクター別[非ウイルス(オリゴヌクレオチド)、ウイルス(レトロウイルス(ガンマレトロウイルス、レンチウイルス))、アデノ随伴]、疾患別(がん、神経疾患)、デリバリー方法別(In Vivo、Ex Vivo)、地域別] ( Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024 / BT 7506) 販売に関する免責事項
[世界の遺伝子治療市場:ベクター別[非ウイルス(オリゴヌクレオチド)、ウイルス(レトロウイルス(ガンマレトロウイルス、レンチウイルス))、アデノ随伴]、疾患別(がん、神経疾患)、デリバリー方法別(In Vivo、Ex Vivo)、地域別] ( Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024 / BT 7506) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆